Claims for Patent: 9,193,791

Summary for Patent: 9,193,791

Title:	Development of masked therapeutic antibodies to limit off-target effects
Abstract:	In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.
Inventor(s):	Williams; John C. (Monrovia, CA), Zer; Cindy (Whittier, CA), Avery; Kendra N. (Pasadena, CA)
Assignee:	City of Hope (Duarte, CA)
Application Number:	13/424,272
Patent Claims:	1. A mask molecule comprising domain IV of a HER2 receptor which binds to trastuzumab monoclonal antibody (mAb) or an antigen-binding fragment thereof and an Fc portion of an IgG1 molecule connected by a linker comprising VPLSLYS (SEQ ID NO: 3) that is cleavable by a matrix metalloproteinase-9 (MMP-9) protease specific to a target tissue. 2. The masked molecule of claim 1, wherein the linker is SEQ ID NO:7. 3. The masked molecule of claim 1, wherein the linker is SEQ ID NO:4. 4. The mask molecule of claim 1 further binds to trastuzumab mAb or the antigen-binding fragment thereof to form a masked trastuzumab or antigen-binding fragment thereof.

Details for Patent 9,193,791

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-08-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-08-03
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2030-08-03